Merck KGaA Agrees to Acquire Bio-Techne for $11.3 Billion
June 25, 2026
Merck KGaA (Darmstadt, Germany) has signed a definitive agreement to acquire Bio-Techne in an all-cash transaction valued at approximately $11.3 billion ($73 per share). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.
- Buyers
- Merck KGaA
- Targets
- Bio-Techne Corporation
- Industry
- Healthcare Services
- Location
- Minnesota, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.